MDxHealth SA
As of Oct 22, 2026, MDxHealth SA is in Stage 1, the basing phase, now in week 8 (since Sep 1, 2026). It closed at $0.18, 96.3% below its 52-week high and below its 200-day average, which is falling.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is MDXH early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
MDXH among Diagnostics & Research42nd of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …42 | MDXH | Stage 1 · wk 8 | 5 | −69.6% |
MDxHealth SA: quick answers
What stage is MDxHealth SA in?
As of Oct 22, 2026, MDxHealth SA (MDXH) is in Stage 1, the basing phase. It entered Stage 1 on Sep 1, 2026 and is in week 8. What the four stages mean
Is MDxHealth SA in an uptrend?
Not yet. MDxHealth SA is in Stage 1, a base that can come before an uptrend. It trades 88.7% below its 200-day average, which is falling.
How far is MDxHealth SA from its 52-week high?
MDxHealth SA closed at $0.18 on Oct 22, 2026, 96.3% below its 52-week high of $5.00. Its 52-week low is $0.18.
How has MDxHealth SA performed over the past year?
As of Oct 22, 2026, MDxHealth SA is down 95.5% over the past year and down 94.6% so far in 2026.
Which sector and industry is MDxHealth SA in?
MDxHealth SA is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.